CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH In a study originally published in Multiple Sclerosis and Related Disorders, alemtuzumab infusion resulted in significantly improved MS-COG scores in the patients evaluated after 12 months, with scores improving from an initial mean of -0.36, to 0.61.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
